Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases
Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQSRPT) and its peers.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 6.3%. This drop is a stark contrast from the S&P 500’s 5.1% gain.
The stock fell over 7% on Thursday after reports that federal health officials under the Trump administration are re-evaluating Moderna's $590 million contract for bird flu vaccine development.
The Donald Trump administration is contemplating the withdrawal of a $590 million contract previously granted to Moderna Inc. (NASDAQMRNA) by the Biden administration. This contract was intended for the production of a bird flu vaccine.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Shares of biotechnology company Moderna (NASDAQMRNA)
jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 financial results. Despite this, Barclays seems to be exercising caution, downgrading the stock to equal weight from overweight earlier in the morning. The firm cited "policy risks, fewer clinical catalysts, and broader economic uncertainties that could limit its upside.".
